ImmuneOnco Terminates Axion Licenses, Regains Global Rights to IMM2510 and IMM27M
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG: 1541) announced it has terminated its License and Collaboration Agreement...
HutchMed’s Sovleplenib Meets Phase 3 Primary Endpoint in wAIHA, Targets NDA Filing
HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced that the Phase 3 registration part of the...
Structure Therapeutics Licenses GLP-1 Patents to Roche for $100 Million Upfront
Structure Therapeutics Inc. (NASDAQ: GPCR) announced that its wholly‑owned subsidiary, Gasherbrum Bio, entered into a...
Sichuan Biokin’s BL-B01D1 ADC Wins Priority Review for ESCC in China
Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that iza-bren (izalontamab brengitecan, BL-B01D1), its first‑in‑class...
Ikarovec and VectorBuilder Sign $1 Billion AAV Capsid Deal for AMD Gene Therapy
Ikarovec, a UK‑based gene therapy company, and VectorBuilder, a leader in gene delivery, announced a...
Zai Lab’s Repotrectinib Wins NMPA sNDA for NTRK Fusion-Positive Solid Tumors
Zai Lab Ltd. (NASDAQ: ZLAB, HKG: 9688) announced that the supplemental New Drug Application (sNDA)...
Mabwell Partners with Sentonix on Neurodegenerative Disease Drug Discovery Alliance
Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) announced a global strategic cooperation agreement with Sentonix,...
Amgen Acquires Dark Blue Therapeutics for $840 Million to Expand AML Portfolio
Amgen Inc. (NASDAQ: AMGN) announced the acquisition of Dark Blue Therapeutics Ltd., a privately held...
BeOne’s Sonrotoclax Wins Conditional NMPA Approval for BCL-2 Inhibitor in CLL/SLL and MCL
BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced that its self‑developed Class 1 innovative drug...
XtalPi’s RTX-117 Wins NMPA IND for CMT Therapy
ReviR Therapeutics, an incubated company of XtalPi (HKG: 2228), announced that RTX-117 has received Investigational...
Ascentage’s PROTAC BTK Degrader APG-3288 Wins FDA IND for B-Cell Malignancies
Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) announced that the U.S. Food and Drug Administration (FDA)...
Takeda and Protagonist Submit Rusfertide NDA for Polycythemia Vera
Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) and Protagonist Therapeutics, Inc. (NASDAQ: PTGX) announced...
Sanofi’s Tzield Wins FDA Priority Review for Pediatric T1D Expansion
Sanofi (NASDAQ: SNY) announced that the U.S. Food and Drug Administration (FDA) has accepted for...
Novo Nordisk, Lilly Cut China Prices for Wegovy, Mounjaro by Up to 80%
Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) have lowered list prices for their...
Lilly Nears $1 Billion Deal for Ventyx’s IBD Pipeline
Eli Lilly (NYSE: LLY) is in advanced talks to acquire Ventyx Biosciences for more than...
Nimbus Therapeutics Partners with Eli Lilly on $1.3 Billion Obesity Drug Deal
Nimbus Therapeutics announced a multi‑year research collaboration and global exclusive licensing agreement with Eli Lilly...
Yifan Pharmaceutical’s F-652 Wins NMPA IND for GVHD Therapy
Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced that its Recombinant Human Interleukin‑22‑Fc Fusion Protein for...
NMPA Releases Draft 102nd Reference Preparations List for Generic Drugs
The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) released the...
Mabwell’s SynuSight Licenses PET Tracer 18F-FD4 to ABLi for Parkinson’s Trials
Mabwell (688062.SH) announced that its incubated investment company, SynuSight Biotech, has signed a non‑exclusive clinical...
Earendil Labs Partners with Sanofi on $2.56 Billion Bispecific Antibody Deal for Autoimmune Diseases
Earendil Labs, the overseas subsidiary of Helixon, announced a strategic collaboration with Sanofi (NASDAQ: SNY)...